Patents Represented by Attorney Michael D. Alexander

Find this attorney in the Justia Lawyer Directory

  • Sprayer actuating device
    Patent number: 6321952
    Abstract: The invention concerns a sprayer (12) actuating device comprising a support (22) whereon the sprayer (12) is supported and a member (24) actuating the sprayer knob (18) mobile axially relative to the support by action of the control means (34, 36, 43, 46, 47, 58) between a position driving in the knob (18) and a position releasing it, the control means (34, 36, 43, 47, 58) comprising elastic means (36) for urging the actuating member in depressing position and means capable of disengaging (58) the lock of the actuating member into releasing position. The control means comprise a rotatable handle (43) manually actuated by a user and associated to a cam (43) moving the actuating member (24) from the depressing position to the releasing position.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: November 27, 2001
    Assignee: Sanofiosynthelabo
    Inventors: Didier Cassier, Brigitte Illel, Henry Saunal
  • Method of treating a tumor
    Patent number: 6319923
    Abstract: In accordance with the present invention there is provided a method of treating a mammal having a solid tumor, the method comprising: a) administering to the mammal an effective amount of 3-ainino-1,2,4-benzotriazine 1,4-dioxide; b) administering to the mammal an effective amount of paclitaxel; and c) administering to the mammal an effective amount of a platinum complex. The method provides unexpected synergistic efficacy. The invention further provides a kit for treatment of a mammalian tumor comprising 3-amino-1,2,-benzotriazine 1,4-dioxide, paclitaxel and a platinum complex.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: November 20, 2001
    Assignee: Sanofi-Synthelabo Inc.
    Inventors: Daniel L. Dexter, Paul E. Juniewicz, James B. Rake, Daniel D. Von Hoff
  • N-(arylsulfonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
    Patent number: 6313120
    Abstract: The invention relates to compounds of formula in which R1 to R9, R16 and R17 are as defined in Claim 1. These compounds are pharmacologically active.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: November 6, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Bernard Ferrari, Jean Gougat, Claude Muneaux, Yvette Muneaux, Pierre Perreaut, Claudine Planchenault
  • Therapeutic use of compounds with &bgr;3-agonist activity
    Patent number: 6310050
    Abstract: The invention relates to the method of use of compounds with B3-agonist activity for inhibiting uterine contractions, preventing or slowing down premature labor, or for the treatment and/or prophylaxis of dysmenorrhea.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: October 30, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Charles Advenier, Luciano Manara
  • Oxaliplatin formulations
    Patent number: 6306902
    Abstract: The invention relates to pharmaceutically stable oxaliplatin solution formulations, to the method of use thereof in the treatment of cancer tumors, to processes for the preparation of such formulations, and to a method for stabilizing solutions of oxaliplatin.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: October 23, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Nicholas H. Anderson, Ross Blundell, Stephen Brown, David A. England, Martin R. Gray
  • Pharmaceutical formulations in dry form for the oral administration of a cyclic quaternary ammonium compound
    Patent number: 6303626
    Abstract: The pharmaceutical formulations according to the invention contain from 0.5 to 50% by weight of a cyclic quaternary ammonium compound and pharmaceutically appropriate excipients and are formulated by wet granulation, preferably with polysorbate 80.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: October 16, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Bernard Abramovici, Xavier Boulenc, Jean-Claude Gautier, Pol Vilain
  • Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
    Patent number: 6291672
    Abstract: Compounds of the formula are useful as human NK3 receptor antagonists.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: September 18, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Daniel Bichon, Xavier Emonds-Alt, Patrick Gueule, Vincenzo Proietto, Didier Van Broeck
  • Stable freeze-dried pharmaceutical formulation
    Patent number: 6284277
    Abstract: The subject of the invention is a freeze-dried formulation consisting of an amorphous phase and a crystalline phase, which is pharmaceutically acceptable, comprising at least one nonprotein active ingredient, characterized in that it contains mannitol and alanine in a ratio R of between 0.1 and 1, R representing the mass of mannitol to the mass of alanine.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: September 4, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Colette Bouloumie, Thierry Breul, Laurence Colliere, Philippe Faure
  • Method of tumor treatment
    Patent number: 6277835
    Abstract: The present invention provides methods for treating mammalian cancer tumors, preferably solid tumors, comprising administering to a mammal in need of such treatment an effective amount of a 1,2,4-benzotriazine oxide as defined in Formula I or pharmacologically acceptable salts of said compound; and administering to the mammal from about one half hour to about twenty-four hours after administering the 1,2,4-benzotriazine oxide an effective amount of a chemotherapy agent to which the tumor is susceptible. The invention also provides kits for treatment of such tumors which comprise a chemotherapy agent and a cytotoxicity-enhancing amount of a 1,2,4-benzotriazine oxide as defined in Formula I.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: August 21, 2001
    Assignee: The Board of Trustees of Leland Stanford Junior University
    Inventor: J. Martin Brown
  • Azacycloalkane derivatives, preparation and therapeutic application
    Patent number: 6262060
    Abstract: The invention relates to azacycloalkane derivatives, to pharmaceutical compositions containing them, to processes for preparing them, and to methods for the treatment of hyperglycaemia, diabetes, obesity or inflammation utilizing them.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: July 17, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Manuel Bedoya-Zurita, Juan Antonio Diaz Martin, Marc Daumas
  • Use of sulphonanilide derivatives to obtain a medicine for treating retrograde ejaculation or aspermia
    Patent number: 6248786
    Abstract: Descriptive summary: use of a compound with the formula (I) where R1 is a hydrogen atom, a C1-2 alkyl group, a C1-2 fluoroalkyl group or a C1-2 perfluoroalkyl group and R2, R3 and R4, which may be the same or different, all represent a hydrogen atom, a straight- or branched-chain C1-4 alkyl group or a C3-4 cycloalkyl group, and R5 is a hydrogen atom, a halogen such as fluorine or chlorine, a C1-4 alkyl group or a straight- or branched-chain C1-4 alkoxy group to manufacture a medicinal agent which can be used to treat ejaculation problems such as retrograde ejaculation or aspermia.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: June 19, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Itzchak Angel, Denis Martin, Sonia Arbilla
  • Disubstituted glutarimide method for preparing same, and use thereof
    Patent number: 6242607
    Abstract: The invention relates to glutarimides of formula (I): in which Ar represents a phenyl non substituted or substituted one or more times with one of the substituents selected from a halogen atom, a hydroxyl, a (C1-C4)alkoxy, a trifluoromethyl, a (C1-C4)alkyl, said substituents being identical or different; a pyridyl group; a thienyl group and X is methylene or ethylene, their salts and their enantiomers, as well as their method of preparation and their use for the preparation of the corresponding 3,3-disubstituted piperidines.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: June 5, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Philippe Camus, Marcel Descamps, Joël Radisson
  • Use of agonists of adrenergic &bgr;-3 receptors for preparing wound-healing medicines
    Patent number: 6235793
    Abstract: The invention relates to the use of &bgr;3-adrenergic receptor agonists for the preparation of healing drugs and to the pharmaceutical compositions for said use.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: May 22, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: André Bernat, Jean-Marc Herbert, Michèle Arnone
  • Use of amines to produce drugs for preventing tumor cell proliferation
    Patent number: 6235791
    Abstract: The present invention relates to the use of compounds capable of displacing tritiated cis-N-cyclohexyl-N-ethyl [3-(3-chloro-4-cyclohexylphenyl)-allyl]amine from its receptors for the preparation of pharmaceutical compositions intended to combat cell proliferation.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: May 22, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Jean Claude Breliere, Pascual Ferrara, Christine Lebouteiller, Raymond Paul, Jorge Rosenfeld, Didier Van Broeck
  • 8-azabicyclo[3.2.1] octane-3-methanamine derivatives as ligands of D2 and D3 dopamine and 5HT1A and 5HT2 serotonin receptors
    Patent number: 6221879
    Abstract: Compounds of general formula (I) in which U represents a group of general formula (A) or (B) in which formulae V represents a hydrogen or halogen atom, a (C1-C3)alkyl group or one or two (C1-C3)alkoxy groups, W and X each represent, respectively, either two oxygen atoms, or an oxygen atom and a CH2 group, or a CH2 group and an oxygen atom, or an oxygen atom and a CO group, n represents the number 0 or 1, R represents either a propyl group when U represents a group of general formula (A), or a hydrogen atom or a (C1-C3)alkyl group when U represents a group of general formula (B), Y represents one or more atoms or groups chosen from the following: hydrogen, halogen, (C1-C3)alkyl and (C1-C3)alkoxy, Z represents two hydrogen atoms or an oxygen atom.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: April 24, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Benoit Marabout, Mireille Sevrin, Pascal George, Jean-Pierre Merly, Daniele De Peretti, Jocelyne Roy, David Machnik
  • Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an HMG-CoA-reductase inhibitor
    Patent number: 6218403
    Abstract: The present invention relates to a pharmaceutical composition containing: (a) a thienopyridine derivative of formula  in which R is hydrogen or a (C1-C4)alkoxycarbonyl group, or one of its pharmaceutically acceptable salts; and (b) an HMG-CoA reductase inhibitor.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: April 17, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Georges Daste, Jean Marc Herbert
  • Method for preparing bromomenthyl-biphenyl derivatives
    Patent number: 6214999
    Abstract: The present invention relates to a process for the preparation of 4′-bromomethyl-biphenyl derivatives of the formula: by reacting a 4′-methyl-biphenyl derivative of the formula: with a brominating agent a in a hydrobromic acid/alkali metal bromate system in a two-phase medium, and under photo-iradiation, where R is as defined in the specification.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: April 10, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Michel Biard, Bertrand Castro
  • Imidazole derivatives, preparation and therapeutic application thereof
    Patent number: 6200991
    Abstract: A compound of formula (I) the process of preparing compounds of formula (I), their pharmaceutical compositions, and the method of treating diseases associated with M3 muscarinic and/or S—HT4 serotoninergic receptors.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: March 13, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Gilles Courtemanche, Gérard DeFosse, Olivier Crespin, Philippe Bovy
  • Pharmaceutical formulations containing poorly soluble drug substances
    Patent number: 6197787
    Abstract: A method for preparing pharmaceutical formulations of poorly soluble drug substances in the form of concentrated solutions for filling soft gelatin capsules and solid dispersions and suspensions for filling hard gelatin capsules and compressing into tablets is provided. Pharmaceutical formulations of poorly soluble drug substances are also disclosed. The formulations include the sodium salt of the poorly soluble drug substance, a conversion aid such as PEG, polysorbate, a sugar alcohol (e.g. mannitol or xylitol), propylene glycol or transcutol, and, in some cases an excipient, such as dicalcium phosphate dihydrate, lactose monohydrate, or microcrystalline cellulose.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: March 6, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Nancy M. Franson, Micael A. Guillot, Sharon M. Laughlin, William L. Rocco
  • Pharmaceutical composition for oral administration
    Patent number: 6191137
    Abstract: The present invention relates to an aqueous solution containing 1-[2-(2-naphthyl)ethyl]-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride (hydrochloride of SR 57746), also comprising &bgr;-cyclodextrin (&bgr;-CD) and a pharmaceutically acceptable acid or buffer to give a pH of less than or equal to 3.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: February 20, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Claude Aleman, Philippe Bastard, Marielle Bonnel, Thierry Breul